

The authors did not provide the reasons for ICU admission of patients. It was also unclear what reasons resulted in such significant decreases in postoperative hemoglobin levels within a short 3-day period after ICU admission. We are concerned that any imbalance in these factors would have confounded interpretation of their results.

Finally, a limitation of this study design is that the decision to perform postoperative transfusions is mainly based on the hemoglobin levels rather than on a patient's status. In clinical practice, it may be unrealistic to use the hemoglobin threshold as the only endpoint to guide decisions regarding transfusion. The coexisting morbidities (e.g., coronary artery disease) also are major determinants of the need for transfusion.<sup>10</sup> In the studies by Carson *et al.*,<sup>2,3</sup> the restrictive transfusion strategy allows transfusion for symptoms of anemia, which are chest pain thought to be cardiac in origin, symptoms and signs of congestive heart failure, or hypotension or tachycardia unresponsive to fluid challenge. Thus, we consider that for ICU patients with physiological instability, this study limitation may be one of the reasons for poorer short-term outcomes with a restrictive transfusion strategy.

### Competing Interests

The authors declare no competing interests.

**Fu-Shan Xue, M.D., Gao-Pu Liu, M.D., Rui-Ping Li, M.D.**  
Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China (F-S.X.). xuefushan@aliyun.com

### References

- Pinheiro de Almeida J, Vincent JL, Barbosa Gomes Galas FR, Pinto Marinho de Almeida E, Fukushima JT, Osawa EA, Bergamin F, Lee Park C, Nakamura RE, Fonseca SM, Cutait G, Inacio Alves J, Bazan M, Vieira S, Vieira Sandrini AC, Palomba H, Ribeiro U Jr, Crippa A, Dalloglio M, Del Pilar Estevez Diz M, Kalil Filho R, Costa Auler JO Jr, Rhodes A, Hajjar LA: Transfusion requirements in surgical oncology patients: A prospective, randomized controlled trial. *ANESTHESIOLOGY* 2015; 122:29–38
- Carson JL, Sieber F, Cook DR, Hoover DR, Noveck H, Chaitman BR, Fleisher L, Beaupre L, Macaulay W, Rhoads GG, Paris B, Zagorin A, Sanders DW, Zakriya KJ, Magaziner J: Liberal *versus* restrictive blood transfusion strategy: 3-year survival and cause of death results from the FOCUS randomised controlled trial. *Lancet* 2015; 385:1183–9
- Carson JL, Terrin ML, Noveck H, Sanders DW, Chaitman BR, Rhoads GG, Nemo G, Dragert K, Beaupre L, Hildebrand K, Macaulay W, Lewis C, Cook DR, Dobbins G, Zakriya KJ, Apple FS, Horney RA, Magaziner J; FOCUS Investigators: Liberal or restrictive transfusion in high-risk patients after hip surgery. *N Engl J Med* 2011; 365:2453–62
- Greenblatt DY, Kelly KJ, Rajamanickam V, Wan Y, Hanson T, Rettammel R, Winslow ER, Cho CS, Weber SM: Preoperative factors predict perioperative morbidity and mortality after pancreaticoduodenectomy. *Ann Surg Oncol* 2011; 18:2126–35
- Garg T, Chen LY, Kim PH, Zhao PT, Herr HW, Donat SM: Preoperative serum albumin is associated with mortality and complications after radical cystectomy. *BJU Int* 2014; 113:918–23
- Kheterpal S, O'Reilly M, Englesbe MJ, Rosenberg AL, Shanks AM, Zhang L, Rothman ED, Campbell DA, Tremper KK: Preoperative and intraoperative predictors of cardiac adverse events after general, vascular, and urological surgery. *ANESTHESIOLOGY* 2009; 110:58–66
- Reich DL, Bennett-Guerrero E, Bodian CA, Hossain S, Winfree W, Krol M: Intraoperative tachycardia and hypertension are independently associated with adverse outcome in noncardiac surgery of long duration. *Anesth Analg* 2002; 95:273–7
- Charlson ME, MacKenzie CR, Gold JP, Ales KL, Topkins M, Fairclough GP Jr, Shires GT: The preoperative and intraoperative hemodynamic predictors of postoperative myocardial infarction or ischemia in patients undergoing noncardiac surgery. *Ann Surg* 1989; 210:637–48
- Wu WC, Smith TS, Henderson WG, Eaton CB, Poses RM, Uttley G, Mor V, Sharma SC, Vezeridis M, Khuri SF, Friedmann PD: Operative blood loss, blood transfusion, and 30-day mortality in older patients after major noncardiac surgery. *Ann Surg* 2010; 252:11–7
- Jung DH, Lee HJ, Han DS, Suh YS, Kong SH, Lee KU, Yang HK: Impact of perioperative hemoglobin levels on postoperative outcomes in gastric cancer surgery. *Gastric Cancer* 2013; 16:377–82

(Accepted for publication May 21, 2015.)

## Adding a New Piece to the Transfusion Puzzle in Oncologic Surgery Patients

To the Editor:

We read with interest the recent article by Pinheiro de Almeida *et al.*<sup>1</sup> regarding transfusion requirements in patients undergoing surgery for intraabdominal malignancies.

In contrast to the results from multiple other large-scale, randomized controlled trials, which did not show substantial differences in outcomes between restrictive and liberal blood transfusion strategies in a variety of different patient cohorts, the current study reports improved outcomes in patients that were transfused at a higher hemoglobin threshold (9 g/dl).<sup>2–4</sup> It is unclear whether this improvement is unique to this particular patient population (patients undergoing surgical resection for solid intraabdominal tumors) or whether the results could be generalized to all patients undergoing surgery for resection of solid tumors.

The authors suggest that the improved outcomes could be related to utilization of leukodepleted blood as well as shorter duration of blood storage compared with other studies. However, there are no convincing data to date that transfusion of leukodepleted blood is associated with improved mortality or reduced incidence of cancer recurrence.<sup>5,6</sup> Similarly, an association between the duration of erythrocyte storage and meaningful clinical outcomes such as increased mortality or long-term morbidities remains uncertain at this time.<sup>7–9</sup> It is noteworthy that the mortality difference was driven by the incidence of septic shock (24 of 31 patients), suggesting the possibility that higher hemoglobin concentrations may protect against septic shock physiology. However, the larger prospective trial by Holst *et al.*,<sup>3</sup>

which was specifically focused on patients with septic shock, failed to demonstrate any advantage to liberal transfusion.

One concern is whether the study by Pinheiro de Almeida *et al.*<sup>1</sup> had a sufficient number of patients upon which to set transfusion policies. Although the study was powered to assess a difference in primary outcome, it was not necessarily powered to achieve balance by randomization. For example, we note that the restrictive strategy group had twice the number of Whipple-type procedures, had a higher incidence of intraabdominal infections, twice the number of radical cystectomies, and a higher incidence of coronary artery disease and congestive heart failure. Imperfect randomization is a natural consequence of a smaller sample size. Furthermore, a large number of patients were excluded from this study, which further questions the generalizability of the study results.

Finally, there are potentially two distinct risk periods following major cancer surgery; the first is the intraoperative and immediate postoperative period when there is an increased risk of death due to blood loss and dilutional anemia. This risk may possibly be mitigated by blood transfusion as anemia in the early postoperative period is associated with increased risk of mortality in patients with cancer.<sup>1,10</sup> The second risk period occurs after discharge from hospital when patients may be at increased risk of cancer recurrence. Although blood transfusion is the mainstay therapy for perioperative anemia, there is the hypothesis that transfusion leads to a nonspecific immunosuppression and increased the risk of cancer recurrence.<sup>10–12</sup> However, this phenomenon has not been studied prospectively and remains controversial. Clearly, if a patient does not survive the immediate postoperative period, then cancer recurrence is not a relevant outcome. The critical unanswered question is where the “risk/benefit” threshold lies. Unfortunately, the authors do not provide data on long-term outcomes and cancer recurrence in their study population and only address early postoperative outcomes.

At this time, it remains unclear what criteria should be used to make the decision to transfuse or not, in order to balance the benefit of transfusion regarding perioperative mortality against the potential risk of transfusion regarding cancer recurrence. This balance likely varies based on a variety of factors including patient comorbidities, cancer type, and the extent of disease.<sup>11</sup> We will need additional prospective trials to refine the indications for blood transfusion following cancer surgery. Although Pinheiro de Almeida *et al.*<sup>1</sup> should be commended for their well-conducted study, which provides important new information in the perioperative transfusion literature, the practical question of whom and when to transfuse patients undergoing oncologic surgery to achieve “best outcomes” remains unanswered.

### Competing Interests

The authors declare no competing interests.

**Milad Sharifpour, M.D., M.S., Edward A. Bittner, M.D., Ph.D., Walter H. Dzik, M.D.** Massachusetts General Hospital, Boston, Massachusetts (M.S.). msharifpour@partners.org

### References

1. Pinheiro de Almeida J, Vincent JL, Barbosa Gomes Galas FR, Pinto Marinho de Almeida E, Fukushima JT, Osawa EA, Bergamin F, Lee Park C, Nakamura RE, Fonseca SM, Cutait G, Inacio Alves J, Bazan M, Vieira S, Vieira Sandrini AC, Palomba H, Ribeiro U Jr, Crippa A, Dalloglio M, Del Pilar Estevez Diz M, Kalil Filho R, Costa Auler JO Jr, Rhodes A, Hajjar LA: Transfusion requirements in surgical oncology patients: A prospective, randomized controlled trial. *ANESTHESIOLOGY* 2015; 122:29–38
2. Hébert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E: A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. *N Engl J Med* 1999; 340:409–17
3. Holst LB, Haase N, Wetterslev J, Wernerman J, Guttormsen AB, Karlsson S, Johansson PI, Aneman A, Vang ML, Winding R, Neblich L, Nibro HL, Rasmussen BS, Lauridsen JR, Nielsen JS, Oldner A, Pettilä V, Cronhjort MB, Andersen LH, Pedersen UG, Reiter N, Wiis J, White JO, Russell L, Thornberg KJ, Hjortrup PB, Müller RG, Møller MH, Steensen M, Tjäder I, Kilsand K, Odeberg-Wernerman S, Sjøbø B, Bundgaard H, Thyø MA, Lodahl D, Mærkedahl R, Albeck C, Illum D, Kruse M, Winkel P, Perner A; TRISS Trial Group; Scandinavian Critical Care Trials Group: Lower *versus* higher hemoglobin threshold for transfusion in septic shock. *N Engl J Med* 2014; 371:1381–91
4. Carson JL, Terrin ML, Noveck H, Sanders DW, Chaitman BR, Rhoads GG, Nemo G, Dragert K, Beaupre L, Hildebrand K, Macaulay W, Lewis C, Cook DR, Dobbin G, Zakriya KJ, Apple FS, Horney RA, Magaziner J; FOCUS Investigators: Liberal or restrictive transfusion in high-risk patients after hip surgery. *N Engl J Med* 2011; 365:2453–62
5. Dzik WH: Leukoreduction of blood components. *Curr Opin Hematol* 2002; 9:521–6
6. Harlaar JJ, Gosselink MP, Hop WC, Lange JF, Busch OR, Jeekel H: Blood transfusions and prognosis in colorectal cancer: Long-term results of a randomized controlled trial. *Ann Surg* 2012; 256:681–6; discussion 686–7
7. Auburn C, Baily M, McQuilton Z, Pilcher D, Hegarty C, Martinelli A, Magrin G, Irving D, Cooper DJ, Bellomo R: Duration of red blood cell storage and outcome in critically ill patients. *J Crit Care* 2014; 476:e1–8
8. Wang D, Sun J, Solomon SB, Klein HG, Natanson C: Transfusion of older stored blood and risk of death: A meta-analysis. *Transfusion* 2012; 52:1184–95
9. Lelubre C, Vincent JL: Relationship between red cell storage duration and outcomes in adults receiving red cell transfusions: A systematic review. *Crit Care* 2013; 17:R66
10. Knight K, Wade S, Balducci L: Prevalence and outcomes of anemia in cancer: A systematic review of the literature. *Am J Med* 2004; 116(Suppl 7A):11S–26S
11. Cata JP, Wang H, Gottumukkala V, Reuben J, Sessler DI: Inflammatory response, immunosuppression, and cancer recurrence after perioperative blood transfusions. *Br J Anaesth* 2013; 110:690–701
12. Wang CC, Iyer SG, Low JK, Lin CY, Wang SH, Lu SN, Chen CL: Perioperative factors affecting long-term outcomes of 473 consecutive patients undergoing hepatectomy for hepatocellular carcinoma. *Ann Surg Oncol* 2009; 16:1832–42

(Accepted for publication May 21, 2015.)